Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (68669)	10/26/2000 7:07:37 PM
From: Jim Bishop	Respond to of 150070

ZiaSun, Former President Anthony Tobin, and Promoter Bryant Cragun Drop Lawsuit and Agree to Pay Opposition Thousands WEDNESDAY, OCTOBER 25, 2000 2:52 AM - BusinessWire SAN DIEGO, Oct 25, 2000 (BUSINESS WIRE) -- Plaintiffs in two closely watched "cyberexpose" lawsuits have agreed to drop all of their charges against a group of online message board posters and have also agreed to pay one of the defendants $60,000. ZiaSun Technologies Inc. (OTCBB:ZSUN), a San Diego-based company, sued unrelated Internet posters George Joakimidis, Michael Morelock, Floyd Schneider and Stephen N. Worthington in mid-1999 for allegedly waging a cyberexpose campaign against them in Internet chatrooms. ZiaSun, its former president Anthony Tobin and a ZiaSun promoter and fundraiser, Bryant Cragun, alleged that the defendants disseminated false information linking them to criminal behavior, pornography, improper financial interests, false corporate disclosures and illegal business practices. Plaintiffs sought court injunctions against further posting by defendants. They also demanded $500,000 in lost earnings and earning capacity, reimbursement of their costs and attorneys' fees, a public apology and that defendants retract all of their postings. Defendants contended that everything they posted about plaintiffs was absolutely true and therefore, as a matter of law, they could not be held liable. One of the defendants, George Joakimidis, cross-sued ZiaSun, Tobin and Cragun for fraud. In a settlement agreement reached by the parties, plaintiffs dismissed all of their charges against defendants, dropped all of their demands for monetary compensation, dropped their demands that defendants apologize and retract their postings and agreed to pay George Joakimidis $60,000. Except for one news release per side, the parties agreed to make no future publications about one another. George Joakimidis stated: "I am relieved that it is all over. It is perhaps unfortunate that the cases did not go to trial, where I would have been given the opportunity to prove that everything I posted on the various message boards was true. "Cragun and ZiaSun, on the other hand, would have been compelled to substantiate their allegations against me. So why did I agree to an out-of-court settlement? To save time, effort and money and to put this lawsuit behind me." Michael Morelock stated: "I was looking forward to my day in court, but this settlement was too good to pass up. I view this lawsuit as an attempt to stifle free speech that backfired." Floyd Schneider stated: "I feel vindicated. For the same reasons that companies use the Internet as a promotional vehicle, it has also provided the individual investor with the tools to seek out the facts and to be heard." Stephen N. Worthington stated: "This is, in no uncertain terms, a victory for free speech. If you know your facts, you should not be afraid to stand up and fight for the truth. The suit appeared to be an attempt by ZSUN to silence those who have raised questions concerning the operational and valuation issues associated with the company. "The securities markets require full and open discussion of information, including all viewpoints. A public company should not be using its power to sue those with opinions different from the company's, since that would chill the exercise of free speech protected by the First Amendment and thwart the goals of the securities laws." James A. Shalvoy, the defendants' lawyer, noted: "We are seeing more of these cases as the Internet's role in securities transactions increases. Honest posters have nothing to fear. The Internet may be the New Frontier, but the rule of law still applies." For additional information, contact: James A. Shalvoy, attorney for George Joakimidis, Michael Morelock, Floyd Schneider, and Stephen N. Worthington, at 310/796-0447 or jshalvoy@earthlink.net. CONTACT: Law Offices of James A. Shalvoy James A. Shalvoy, 310/796-0447 jshalvoy@earthlink.net URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2000 Business Wire. All rights reserved. KEYWORD: CALIFORNIA INDUSTRY KEYWORD: INTERNET LEGAL/LAW ......

To: StocksDATsoar who wrote (68669)	10/26/2000 7:09:07 PM
From: y2kfree_radical	Respond to of 150070

u wudda seen ur JDSU as low as $63-i'd rather be lucky than good

To: StocksDATsoar who wrote (68669)	10/26/2000 8:51:04 PM
From: myturn	Read Replies (3) \| Respond to of 150070

Someone posted to me a while back companies trading under .20 that were generating revenues of more than 100 million a year. Can that person please post those companies to me again? Thank you Cheers RG

To: StocksDATsoar who wrote (68669)	10/26/2000 10:23:59 PM
From: Aerobleu	Respond to of 150070

DNAP featured in Sarasota Herald-Tribune article dated 10/25/00 newscoast.com Area biotech company gains monied partner By Alexander Coolidge STAFF WRITER A Sarasota biotechnology company has received an infusion of money to help it develop or market future medical research that could lead to treatments based on a patient's genetics. Tony Frudakis, the chief executive of DNAPrint Genomics Inc., said a New Jersey company has bought the first option to develop raw findings into commercial medical products. Under the deal, Orchid BioSciences Inc. of Princeton, N.J., will have the option of shepherding DNAPrint discoveries through further testing and regulatory approvals, then developing and marketing the findings into commercial products. DNAPrint would keep patents on its findings, but Orchid would have the option to license products developed from them. DNAPrint would retain profits reaped from future products. Frudakis said Orchid had the deep pockets needed to turn raw research into something that could be sold. "This helps us focus on research and on generating a portfolio of projects," Frudakis said. "It's a whole other set of headaches to develop commercial products and market them." Frudakis wouldn't say how much his 5-month-old company received in the deal, but said revenues would increase from high five figures to six to seven figures. "We believe this is the wave of the future," Orchid spokeswoman Elizabeth Lindheim said. "These relationships will help personalized medicine develop sooner." Lindheim declined to say how much cash Orchid paid DNAPrint. Neither company would discuss how they would split potential profits under the deal. The news didn't help the two company's stock prices. DNAPrint's over-the-counter shares were selling for 24 cents at the close of regular trading Wednesday, down 1 cent. Orchid's shares, traded on the Nasdaq, were selling for $20, down $3.50, or 17.5 percent. Orchid develops technologies to enhance genetic research and has collaborative agreements with Affymetrix, Sarnoff Corp., Luminex and the SNP Consortium. For the quarter ended June 30, Orchid reported a loss of about $18 million, or 94 cents a share, with revenues of about $4.6 million. Scientists announced in June they had virtually deciphered the human genome, the chemical blueprint of DNA. Experts hope the discovery will lead to better diagnostics and treatments for disease. DNAPrint was founded by a group of scientists with research and commercial experience in high-level mathematics, programming and molecular genetics. The company studies DNA extracted from human blood and is working on numerous projects, including developing a specialized treatment for patients with ovarian cancer. Staff writer Alexander Coolidge can be contacted at 957-5198 or alexander.coolidge@herald-trib.com.

To: StocksDATsoar who wrote (68669)	10/27/2000 9:44:20 AM
From: CIMA	Read Replies (2) \| Respond to of 150070

JDS UNIPHASE'S WHITE-HOT Q1 The optical networking component maker's fiscal Q1 earnings came in looking strong. Will they be enough to reverse this week's mass sell-off in the sector? By Dave Marino-Nachison An upbeat fiscal first-quarter earnings report from fiber optic components leader JDS Uniphase (Nasdaq: JSDU) following last night's bell perked up investors in after-hours trading, pumping the stock 12%, after a 25% plummet on Wednesday. JDSU and other fiber optics companies, such as Sycamore Networks (Nasdaq: SCMR) and Ciena (Nasdaq: CIEN), have been capsized by the wake of Nortel's (NYSE: NT) earnings report from earlier in the week. (Nortel is a major customer of JDSU.) Nortel's optical networking division didn't grow as quickly as some analysts hoped, which compounded another recent disappointment from Lucent (NYSE: LU). But Rule Maker JDSU's results sparkled: Revenues rose 171% year-over-year and, at $785 million, overcame the projections of market watchers. Pro forma net income rose 29% to $0.18 per share, beating Street forecasts by two pennies. fool.com fool.com Now JDSU expects to earn $0.80 per share -- a dime better than expected -- for the fiscal year, CFO Tony Muller reportedly said on a conference call. He also pointed investors toward top-line growth of between 115% and 120%. "Optical demand is good and healthy," a Robertson Stephens analyst told Bloomberg. "We believe demand remains strong,'' COO Charles Abbe was quoted as saying. He maintains the company isn't seeing the inventory channel grow fat at the expense of future sales: "We can't find any meaningful evidence of an industry slowdown.'' Look for Q2 pro forma earnings of $0.19 or $0.20 per share, execs said, compared with $0.17 as projected by Wall Street. While short-term market movements are of little interest to Fools, today's trading should prove interesting as investors work to make sense of the recent rash of seemingly conflicting indications. While some might say the fiber optic sector was merely due for a "correction" of sorts, of greater importance are clues about the sort of demand that lies ahead to justify or confound even today's damaged -- but still extremely high -- valuations. Demand for the components that speed data transmissions and fatten networks to meet skyrocketing bandwidth needs isn't expected to slow significantly for the next several years. For more information, check out a column Richard McCaffery wrote back in July. fool.com _________________________________________________________________